This article is for research and educational purposes only and is not medical advice.
Recombinant human growth hormone (HGH) is one of the most studied protein hormones in endocrine research, in large part because of what happens downstream of it. Much of HGH's biology is read out through a single second-messenger system: the growth hormone receptor, the JAK2/STAT5 signalling cascade, and the production of insulin-like growth factor 1 (IGF-1). This article examines, at a mechanistic level, how laboratory-grade recombinant HGH engages that pathway.
Quick answer: Recombinant HGH (somatropin) binds a preformed growth hormone receptor (GHR) dimer and repositions its two chains. This activates the receptor-associated kinase JAK2, which phosphorylates the receptor tail and the transcription factor STAT5. Phosphorylated STAT5 dimerises, enters the nucleus, and switches on growth hormone target genes — most prominently IGF-1, which is produced largely in the liver and mediates many of HGH's downstream anabolic effects.
Recombinant HGH, known generically as somatropin, is a single-chain protein of 191 amino acids with a molecular mass of roughly 22.1 kDa (about 22,125 Da). It is structurally identical to the growth hormone secreted by the human pituitary gland, which is why research models use it as a faithful stand-in for the endogenous hormone. The "recombinant" label simply refers to how the protein is manufactured rather than to any change in its sequence.
Because the molecule matches pituitary growth hormone, studies that introduce somatropin are effectively probing the same receptor and the same signalling machinery the body uses naturally. Researchers interested in the broader biology of this hormone often start with a primer such as this HGH research guide before moving into the receptor-level mechanics described below.
The growth hormone receptor is a class I cytokine-family receptor. A defining feature of this receptor family is that it has no intrinsic kinase activity of its own — the receptor cannot phosphorylate anything directly. Instead, it relies on an associated kinase that sits on its intracellular tail.
A second important feature is how the receptor is arranged before the hormone ever arrives. Rather than two separate receptor chains coming together when growth hormone binds, the GHR exists as a preformed dimer. A single growth hormone molecule binds across this dimer and repositions the two receptor chains relative to one another. This conformational change — not a change in the number of bound chains — is what initiates signalling. Understanding this "preformed dimer" model corrected an older assumption that the hormone simply glued two receptors together.
The kinase associated with the GHR is JAK2 (Janus kinase 2). When growth hormone repositions the receptor dimer, the two JAK2 molecules bound to the receptor tails are brought into a productive orientation and become active. Activated JAK2 then phosphorylates tyrosine residues on the receptor's own intracellular tail, creating docking sites, and phosphorylates the signal-transducing transcription factors of the STAT family.
The principal STAT recruited by the GHR is STAT5, although STAT1 and STAT3 can also be engaged. The growth hormone receptor additionally couples to other branches, including the MAPK pathway and the PI3K/Akt pathway, which broadens the cellular response beyond transcription alone. JAK2 sits at the top of this network as the obligatory first kinase: without JAK2 activation, the cytokine-class GHR has no way to transmit the hormone's signal inward.
Once STAT5 is phosphorylated by JAK2, it dimerises, translocates from the cytoplasm into the nucleus, and binds DNA to drive transcription of growth hormone target genes. Among these target genes, IGF-1 is the most prominent.
IGF-1 (insulin-like growth factor 1) is produced largely in the liver in response to growth hormone, and it is the messenger that carries out many of growth hormone's growth-promoting and anabolic effects. This relationship is the basis of the classic somatomedin hypothesis, which framed IGF-1 as the circulating intermediary through which pituitary growth hormone acts on peripheral tissues.
IGF-1 itself is a distinct molecule from the hormone that triggers it: a 70-amino-acid peptide of about 7.6 kDa. It also signals through a different kind of receptor. Whereas the GHR is a cytokine-class receptor with no built-in kinase, IGF-1 acts on the IGF-1 receptor (IGF1R), which is a receptor tyrosine kinase — a receptor that carries its own catalytic activity. So the HGH-to-IGF-1 axis actually spans two different receptor classes: a cytokine receptor at the top and a receptor tyrosine kinase at the bottom.
A key concept in this area is the split between growth hormone's direct and indirect effects. Some of growth hormone's actions are exerted directly by the hormone itself — for example, lipolysis (the mobilisation of fat) and antagonism of insulin's actions. Other effects, particularly the anabolic, lean-mass-associated effects, are largely mediated indirectly through IGF-1 rather than by growth hormone acting alone.
This direct-versus-indirect distinction is why the IGF-1 axis is so central to body-composition research. When researchers study how the growth hormone system relates to lean mass and fat handling, they are often really studying two overlapping signals: a direct metabolic signal from growth hormone and an IGF-1-mediated anabolic signal generated downstream of STAT5.
It also explains why not every growth-hormone-related research compound behaves the same way. As a contrast, the C-terminal fragment of growth hormone discussed in our article on HGH Fragment 176-191 is studied for metabolic activity but does not significantly raise IGF-1 — a useful reminder that "derived from growth hormone" does not automatically mean "drives the IGF-1 axis." Researchers comparing mechanisms across compounds may also look at work on the AOD-9604 anti-obesity peptide and at broader body recomposition science.
Does recombinant HGH work directly, or only through IGF-1? Both. Research describes growth hormone as having direct effects that the hormone exerts itself — notably lipolysis and antagonism of insulin's actions — and indirect effects that are mediated by IGF-1. Much of the anabolic, lean-mass-associated signalling is attributed to IGF-1 generated downstream, while certain metabolic effects belong to growth hormone acting directly. This is why the system is often described as a two-signal axis rather than a single linear pathway.
Why does the growth hormone receptor need JAK2 at all? The growth hormone receptor is a class I cytokine-family receptor with no intrinsic kinase activity, meaning it cannot phosphorylate anything on its own. It therefore depends on the associated kinase JAK2 to do the chemistry. When growth hormone repositions the preformed receptor dimer, JAK2 is activated and phosphorylates both the receptor tail and STAT5. Without JAK2, the receptor has no way to convert hormone binding into an intracellular signal.
Where is IGF-1 actually made? In response to growth hormone, IGF-1 is produced largely in the liver, which is the major source of the circulating IGF-1 that classic research associates with growth hormone's downstream effects. This liver-centred view underpins the somatomedin hypothesis, in which IGF-1 acts as the intermediary carrying growth hormone's growth-promoting message to peripheral tissues.
How is IGF-1 different from HGH? They are separate molecules acting through different receptors. Recombinant HGH (somatropin) is a 191-amino-acid protein of about 22.1 kDa that binds the cytokine-class growth hormone receptor. IGF-1 is a smaller 70-amino-acid peptide of about 7.6 kDa that signals through the IGF-1 receptor (IGF1R), a receptor tyrosine kinase that carries its own catalytic activity. So the axis spans two distinct receptor classes from top to bottom.
What role does STAT5 play in this pathway? STAT5 is the principal transcription factor that carries the growth hormone signal into the nucleus. After JAK2 phosphorylates it, STAT5 dimerises, translocates to the nucleus, and drives transcription of growth hormone target genes — IGF-1 prominent among them. STAT1 and STAT3 can also be engaged, and the receptor additionally couples to MAPK and PI3K/Akt branches, but STAT5 is the central link between receptor activation and IGF-1 gene expression.
Comprehensive evidence-based guide to natural weight loss in Australia — caloric balance, diet, exercise, sleep, hormones, GLP-1 medications, and peptide research.
Facial volume loss and skin laxity on GLP-1 medications is real — but not unique to Ozempic. Here's what drives it and how to reduce the effect.
Up to 40% of weight lost on GLP-1 medications like Ozempic and Wegovy can be lean mass. Here's the evidence-based protocol for resistance training, protein intake, and supplementation to protect muscle while maximising fat loss.